Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer can get out of its recent troubles thanks to a deep pipeline and cost-cutting efforts. Medical Properties Trust has ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Intel Corp. Chief Executive Lip-Bu Tan seems to be making interesting moves early in his tenure, but that doesn’t mean he’ll achieve success easily. The company has missed out on the ...

Pfizer's PFE stock has risen 5% since it reported ... keeping track of the company’s newer growth prospects. It will be a great pick for value investors, considering its cheap valuation, as ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to bolster tribal health care services in Oklahoma, with three Indigenous-operated clinics set to receive funding. The one-time ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Both Pfizer and Viking aim to enter the high-growth weight loss drug market. Analysts forecast this market could be worth as much as $130 billion just a few years from now. Big pharmaceutical ...

Other drugmakers are eyeing the market as well. Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...